全文获取类型
收费全文 | 4791篇 |
免费 | 366篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 189篇 |
妇产科学 | 7篇 |
基础医学 | 274篇 |
口腔科学 | 17篇 |
临床医学 | 153篇 |
内科学 | 3394篇 |
皮肤病学 | 64篇 |
神经病学 | 30篇 |
特种医学 | 22篇 |
外科学 | 31篇 |
综合类 | 77篇 |
预防医学 | 53篇 |
眼科学 | 14篇 |
药学 | 158篇 |
中国医学 | 11篇 |
肿瘤学 | 679篇 |
出版年
2023年 | 90篇 |
2022年 | 23篇 |
2021年 | 54篇 |
2020年 | 138篇 |
2019年 | 133篇 |
2018年 | 123篇 |
2017年 | 127篇 |
2016年 | 153篇 |
2015年 | 151篇 |
2014年 | 185篇 |
2013年 | 243篇 |
2012年 | 154篇 |
2011年 | 192篇 |
2010年 | 178篇 |
2009年 | 192篇 |
2008年 | 187篇 |
2007年 | 210篇 |
2006年 | 160篇 |
2005年 | 170篇 |
2004年 | 147篇 |
2003年 | 170篇 |
2002年 | 181篇 |
2001年 | 167篇 |
2000年 | 173篇 |
1999年 | 119篇 |
1998年 | 116篇 |
1997年 | 136篇 |
1996年 | 143篇 |
1995年 | 138篇 |
1994年 | 106篇 |
1993年 | 43篇 |
1992年 | 44篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 33篇 |
1988年 | 36篇 |
1987年 | 36篇 |
1986年 | 20篇 |
1985年 | 80篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 37篇 |
1981年 | 46篇 |
1980年 | 32篇 |
1979年 | 42篇 |
1978年 | 37篇 |
1977年 | 31篇 |
1976年 | 19篇 |
1975年 | 17篇 |
1971年 | 4篇 |
排序方式: 共有5175条查询结果,搜索用时 328 毫秒
101.
102.
103.
Most acute promyelocytic leukaemia (APL) patients suffer from disordered haemostasis. APL can be treated successfully in most instances by all-trans retinoic acid (ATRA) therapy, which induces endpoint maturation of the leukaemic promyelocytes with the characteristic t(15;17). Annexin II (AnII), a profibrinolytic protein, has been implicated in the bleeding manifestation seen in APL. Our group has shown previously that high levels of AnII are expressed on other acute myeloid leukaemia subtypes that are sometimes associated with disordered haemostasis, albeit less frequently than APL. This study examined the effects of ATRA on AnII expression and cell differentiation, on myeloid leukaemia cell lines to determine whether a regulatory influence on AnII may contribute to the return of haemostatic stability in APL following treatment. The results confirmed that AnII expression in the APL cell line (NB4) was significantly downregulated in response to ATRA (P < 0.01), with associated morphological and immunophenotypical evidence of myeloid differentiation. ATRA also downregulated AnII expression on other myeloid cell lines, albeit to a lesser extent than observed on NB4 cells. The results provide evidence that ATRA may resolve the hyperfibrinolysis in APL by downregulation of AnII expression. 相似文献
104.
Forestier E Johansson B Gustafsson G Borgström G Kerndrup G Johannsson J Heim S 《British journal of haematology》2000,110(1):147-153
The prognostic impact of acquired chromosome abnormalities was evaluated in a population-based consecutive series of 768 children (< 15 years of age) with acute lymphoblastic leukaemia (ALL). The study cohort included all cases of cytogenetically abnormal childhood ALL diagnosed between 1986 and 1997 in the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). The probability of event-free survival (pEFS) for the total cohort was 0. 72 +/- 0.02. When comparing the two treatment periods of July 1986 to December 1991 and January 1992 to December 1997, a better survival was seen for the latter time period (pEFS of 0.69 +/- 0.02 vs. 0.76 +/- 0.02, P = 0.05). Hypodiploidy with less than 45 chromosomes, t(9;22)(q34;q11) and 11q23 translocations were associated with a dismal outcome during the whole study period (pEFS of 0.57 +/- 0.12, 0.41 +/- 0.14 and 0.37 +/- 0.10 respectively). The poor prognostic influence of 11q23 rearrangements seemed to be restricted to infants and older children (> 10 years), who differed significantly from children aged 1-10 years in this regard (P < 0. 01). Patients with t(9;22)-positive ALL seemed to benefit from allogeneic bone marrow transplantation in first remission (P = 0.05). The pEFS for children with t(1;19)(q23;p13)-positive ALL was intermediate (0.63 +/- 0.17), with a tendency to a better outcome for patients with the unbalanced variant der(19)t(1;19). Hyperdiploid ALL patients, subdivided into moderate hyperdiploidy (47-51 chromosomes), massive hyperdiploidy (52-60 chromosomes) and cases in the tri-/tetraploid range (> 60 chromosomes) had the best outcome in the last treatment period (pEFS of 0.81 +/- 0.06, 0.80 +/- 0.04 and 0.88 +/- 0.07 respectively), unless t(1;19), t(8;14), t(9;22) or 11q23 translocations were present. In a multivariate analysis including white blood cell (WBC) count, immunophenotype, age, mediastinal mass, central nervous system involvement and leukaemia karyotype, only WBC and modal chromosome number were shown to be significant independent risk factors (P < 0.01). 相似文献
105.
Gloria M. I. Su Mary W. Davey Ross A. Davey Antony D. Kidman 《British journal of haematology》1994,88(3):566-574
Summary. In an attempt to mimic clinical conditions for the treatment of leukaemia, the HL60 promyelocytic cell line was treated for 18 h with low, clinically relevant, levels of the anthracycline epirubicin and the Vinca alkaloid vinblastine. The resulting drug-resistant sublines not only expressed P-glycoprotein and the MDR phenotype but were also cross-resistant to chlorambucil, methotrexate but were also cross-resistant to chlorambucil, methotrexate and cisplatinum, and had increased resistance to radiation. Development of resistance was associatted with an aberrant differentiation phenotype with decreased expression of myeloid antigens and expression of glycophorin A. an antigen normally associated with erythroid differentiation. The ability of HL60 cells to terminally differentiate in response to all- trans -retinoic acid (vitamin A acid) was lost in the sublines. These results suggest that either a single novel mechanism is responsible for multiple drug resistance or the initial response to drug treatment is the co-induction of multiple mechanisms. These cells and the method by which they were generated therefore provide a clinically relevant model for the study of the initial events in the development of not only multidrug resistance but also the extended multiple drug resistance usually encountered in the treatment of leukaemia. 相似文献
106.
Grumbach IM Mayer IA Uddin S Lekmine F Majchrzak B Yamauchi H Fujita S Druker B Fish EN Platanias LC 《British journal of haematology》2001,112(2):327-336
Interferon alpha (IFNalpha) has significant clinical activity in the treatment of patients with chronic myelogenous leukaemia (CML), but the mechanisms of its selective efficacy in the treatment of the disease are unknown. The CrkL adaptor protein interacts directly with the BCR-ABL fusion protein that causes the malignant transformation and is constitutively phosphorylated in BCR-ABL-expressing cells. In the present study, we provide evidence that CrkL was engaged in IFNalpha-signalling in the CML-derived KT-1 cell line, which expresses BCR-ABL and is sensitive to the growth inhibitory effects of IFNalpha. CrkL is constitutively associated with BCR-ABL in these cells and treatment with IFNalpha had no effect on the BCR-ABL/CrkL interaction. After IFNalpha stimulation, CrkL associated with Stat5, which also underwent phosphorylation in an IFNalpha-dependent manner. The interaction of CrkL with Stat5 was facilitated by the function of both the SH2 and the N-terminus SH3 domains of CrkL. The resulting CrkL-Stat5 complex translocated to the nucleus and could be detected in gel shift assays using elements derived from either the beta-casein promoter or the promoter of the PML gene, an IFNalpha-inducible gene that mediates growth inhibitory responses. In addition to its interaction with Stat5, CrkL interacts with C3G in KT-1 cells and such an interaction regulates the downstream activation of the small GTPase Rap1, which also mediates inhibition of cell proliferation. Thus, despite its engagement by BCR-ABL in CML-derived cells, CrkL mediates activation of downstream signalling pathways in response to the activated type I IFN receptor and such signals may contribute to the generation of the anti-proliferative effects of IFNalpha in CML. 相似文献
107.
Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia 总被引:1,自引:0,他引:1
Takeuchi S Takeuchi N Tsukasaki K Bartram CR Zimmermann M Schrappe M Taguchi H Koeffler HP 《British journal of haematology》2002,119(4):985-987
Genetic polymorphisms in the tumour necrosis factor (TNF) locus influence the outcome of non-Hodgkin's lymphoma (NHL). We investigated whether these polymorphisms might contribute to the clinical course of childhood acute lymphoblastic leukaemia (ALL). Genomic DNA from 214 childhood ALL patients was analysed. Patients with a high-risk haplotype were older than patients with low-risk haplotype (P = 0.024). No statistically significant associations were found between TNF haplotype and sex, WBC counts, central nervous system involvement, immunophenotype, response to chemotherapy, and event-free survival. These data suggest that genetic polymorphisms in the TNF locus have a limited effect on the outcome of childhood ALL. 相似文献
108.
109.
P. Stark B. Shohat S. Kadosh M. Shaklai 《International journal of laboratory hematology》1999,21(3):187-192
The immunological dysfunction observed in B-chronic lymphocytic leukaemia (B-CLL) is often related to T-lymphocyte incompetence. The local xenogeneic graft-vs.-host reaction (XGVHR), an assay to evaluate T-lymphocyte function, was performed in 112 untreated B-CLL patients. The XGVHR results significantly correlated with clinical parameters: 37.1% of the patients in the stable phase (Rai stage 0–1–2) and only 13.3% of the patients in the progressive phase (Rai stage 3–4) had positive XGVHR results. Patients with negative results had a higher number and percentage of lymphocytes (25 247 vs. 17 071/μl and 75.9% vs. 65.6%, respectively), much lower T/B lymphocyte ratio (0.37 vs. 0.93), higher WBC count (30 977 vs. 23 458/μl), lower platelet count (158 068 vs. 181 684/μl) and lower levels of IgA and IgM (115.6 vs. 200.5 mg/dl and 80.4 vs. 124.3 mg/dl, respectively) compared to those with positive results. Among those with negative XGVHR results, a higher mortality rate was found in those who had infections compared with those who did not (73.7% vs. 9.1%). In conclusion, the XGVHR assay significantly correlates with important characteristics of B-CLL and may be useful in the clinical evaluation of B-CLL patients. 相似文献
110.
Rosen O Müller HJ Gökbuget N Langer W Peter N Schwartz S Hähling D Hartmann F Ittel TH Mück R Rothmann F Arnold R Boos J Hoelzer D 《British journal of haematology》2003,123(5):836-841
The German Multicentre acute lymphoblastic leukaemia (ALL) study group (GMALL) performed a pilot study using pegylated asparaginase (PEG-ASP) in combination with high-dose methotrexate as consolidation therapy in the 05/93 protocol. The aim of the study was an intra-individual comparison of two different doses of PEG-ASP in 26 patients, with regard to the depletion of asparagine in serum and toxicity. 'Pharmacokinetic' monitoring was performed to evaluate the effect of an intra-individual dose escalation of PEG-ASP from 500 to 1000 U/m2 intravenously in successive doses. Serum asparaginase activity was targeted at > or =100 U/l for 1 week and > or =50 U/l for 10 d. The second course of PEG-ASP was administered to 23 patients. Due to hypersensitivity reactions in five patients, only 18 patients were evaluable for pharmacokinetic monitoring. With respect to the PEG-ASP activity, an effective depletion of asparagine could be postulated in the majority of patients during 10 d after the first administration. The effect of an intraindividual dose escalation form 500 to 1000 U/m2 was evaluable in 17 of 22 patients. An increment in peak PEG-ASP activity >70% was observed in 65% of the patients. PEG-ASP was well tolerated. Despite the long half-life of PEG-ASP, neither pancreatic nor central nervous toxicities occurred among the 26 adult patients treated in this pilot study. 相似文献